Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity - USD ($) $ in Thousands	Total	Series A Non-Voting Convertible Preferred Stock	Series B Non-Voting Convertible Preferred Stock	Common Stock	Preferred Stock Series A Non-Voting Convertible Preferred Stock	Preferred Stock Series B Non-Voting Convertible Preferred Stock	Common Stock	Common Stock Series A Non-Voting Convertible Preferred Stock	Common Stock Series B Non-Voting Convertible Preferred Stock	Common Stock Common Stock	Additional Paid-in Capital	Additional Paid-in Capital Series A Non-Voting Convertible Preferred Stock	Additional Paid-in Capital Series B Non-Voting Convertible Preferred Stock	Additional Paid-in Capital Common Stock	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021	0
Beginning balance at Dec. 31, 2021	$ 0
Ending balance (in shares) at Dec. 31, 2022	0
Ending balance at Dec. 31, 2022	$ 0
Beginning balance (in shares) at Dec. 31, 2021					0	0
Beginning balance (in shares) at Dec. 31, 2021							1,974,000
Beginning balance at Dec. 31, 2021	83,941				$ 0	$ 0	$ 5				$ 425,765				$ (20)	$ (341,809)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs (in shares)							430,000
Issuance of common stock and pre-funded warrants in connection with registered direct offering, net of offering costs	42,874						$ 1				42,873
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)							204,000
Issuance of common stock in connection with employee stock purchase plan (in shares)							6,000
Issuance of common stock in connection with employee stock purchase plan	222										222
Stock-based compensation expense	7,111										7,111
Foreign currency translation adjustment	(35)														(35)
Unrealized (loss) gain on marketable securities	7														7
Net loss	(83,815)	$ 0	$ 0	$ (83,815)												(83,815)
Ending balance (in shares) at Dec. 31, 2022					0	0
Ending balance (in shares) at Dec. 31, 2022							2,614,000
Ending balance at Dec. 31, 2022	$ 50,305				$ 0	$ 0	$ 6				475,971				(48)	(425,624)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)	150,000
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs	$ 84,555
Ending balance (in shares) at Dec. 31, 2023	150,000
Ending balance at Dec. 31, 2023	$ 84,555
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)							905,000
Issuance of stock in connection with private placement, net of financing costs (in shares)					721,000					6,000,000
Issuance of stock in connection with private placement, net of financing costs		197,364		84,555	$ 197,364									$ 84,555
Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract (in shares)					365,000
Issuance of Series A non-voting convertible preferred stock in connection with the asset acquisition of Spyre and settlement of related forward contract	189,741				$ 189,741
Conversion of non-voting convertible preferred stock into common stock (in shares)					(649,000)			25,972,000
Conversion of non-voting convertible preferred stock into common stock		0			$ (202,178)			$ 3				$ 202,175
Issuance of common stock in connection with the asset acquisition of Spyre (in shares)							518,000
Issuance of common stock in connection with the asset acquisition of Spyre	3,768						$ 1				3,767
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)							48,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	405										405
CVR distribution to common stockholders	(29,500)										(29,500)
Stock-based compensation expense	14,347										14,347
Issuance of Parapyre Option Obligation warrants	11,471										11,471
Foreign currency translation adjustment	37														37
Unrealized (loss) gain on marketable securities	313														313
Net loss	$ (338,790)	$ (239,158)	$ (4,749)	(94,883)												(338,790)
Ending balance (in shares) at Dec. 31, 2023		437,037	16,667		437,000	0
Ending balance (in shares) at Dec. 31, 2023	36,057,109						36,057,000
Ending balance at Dec. 31, 2023	$ 184,016				$ 184,927	$ 0	$ 10				763,191				302	(764,414)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs (in shares)	122,000
Issuance of Series B non-voting convertible preferred stock in connection with private placement, net of financing costs	$ 168,850
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock (in shares)						(272,000)
Stockholder approval of the issuance of common stock upon conversion of Series B convertible non-voting preferred stock						$ (253,405)
Ending balance (in shares) at Dec. 31, 2024	0
Ending balance at Dec. 31, 2024	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with exercise of pre-funded warrants (in shares)							250,000
Issuance of common stock in connection with exercise of pre-funded warrants	1										1
Stockholder approval of the issuance of Common Stock upon conversion of Series B convertible non-voting preferred stock (in shares)						272,000
Stockholder approval of the issuance of common stock upon conversion of Series B convertible non-voting preferred stock	253,405					$ 253,405
Exchange of Series A non-voting convertible preferred stock for common stock (in shares)					(91,000)		3,640,000
Exchange of Series A non-voting convertible preferred stock for common stock	0				$ (38,502)		$ 1				38,501
Conversion of non-voting convertible preferred stock into common stock (in shares)						(255,000)			10,198,000
Conversion of non-voting convertible preferred stock into common stock			$ 0			$ (244,010)			$ 1				$ 244,009
Issuance of common stock in connection with at-the-market offerings, net of financing costs (in shares)							777,000
Issuance of common stock in connection with at-the-market offering program, net of financing costs	20,504										20,504
Issuance of common stock in connection with follow-on offerings, net of financing costs (in shares)							8,366,000
Issuance of common stock in connection with follow-on offering, net of financing costs	215,674						$ 1				215,673
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan (in shares)							931,000
Issuance of common stock in connection with exercise of stock options and employee stock purchase plan	7,511										7,511
Stock-based compensation expense	30,374										30,374
Issuance of Parapyre Option Obligation warrants	$ 14,459										14,459
Vesting of restricted stock units (in shares)	38,000
Foreign currency translation adjustment	$ 4														4
Unrealized (loss) gain on marketable securities	(126)														(126)
Net loss	$ (208,018)	$ (47,624)	$ (10,839)	$ (149,555)												(208,018)
Ending balance (in shares) at Dec. 31, 2024		346,045	16,667		346,000	17,000
Ending balance (in shares) at Dec. 31, 2024	60,257,023						60,257,000
Ending balance at Dec. 31, 2024	$ 517,804				$ 146,425	$ 9,395	$ 13				$ 1,334,223				$ 180	$ (972,432)